Free · no account · quoted from the filing

What changed in ABBV's 10-Q

Source: 10-Q filed 2026-08-03 · compared against 10-Q 2026-05-08. Every passage below is quoted verbatim from the filing itself.

Acquisitions

This filing

Under the terms of the agreement, AbbVie will acquire all outstanding shares of Apogee for $135.11 per share in cash for a total value of approximately $10.9 billion.

Profitability verified

Prior filing

Other expense, net 2,306 1,445

This filing

Other expense, net 1,475 2,662

Acquired IPR&D verified

Prior filing

Acquired IPR&D and milestones 744 248

This filing

Acquired IPR&D and milestones 291 823

Revenues verified

Prior filing

Net revenues $ 15,002 $ 13,343

This filing

Net revenues $ 16,990 $ 15,423

Tax Rate verified

Prior filing

The increase in the effective tax rate for the three months ended March 31, 2026 over the prior year was primarily due to the increased impact of changes in fair value of contingent consideration

This filing

The decrease in the effective tax rate for the three and six months ended June 30, 2026 over the prior year was primarily due to the decreased impact of changes in fair value of contingent consideration

Liquidity verified

Prior filing

Operating activities $ 3,829 $ 1,635

This filing

Operating activities $ 7,265 $ 6,788

What it means — the analyst reading

The passages above are the company's own words. The plain-English reading of them — what changed, why it matters, and the direction of travel — is part of the Filing Change Monitor.

See the Filing Change Monitor →

Compared from narrative excerpts (outlook, risks, MD&A) of both filings. Every quotation shown was checked character-for-character against the filing it is attributed to. Not advice. Source: company SEC filings via stockportfolio.pro. Educational, not investment advice.